Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kojiro Tashiro

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
International Cancer Conference Journal|January 27, 2026
Pathological diagnosis and therapeutic management of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinomaKojiro Tashiro, Yoji Nagashima, Mikiko Kaneko, et al.
Clinical Genitourinary Cancer|April 21, 2024
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate CancerKojiro Tashiro, Shoji Kimura, Shunsuke Tsuzuki, et al.
International Journal of Clinical Oncology|July 11, 2023
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancerKeiichiro Miyajima, Hirotaka Suzuki, Fumihiko Urabe, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
Urologic Oncology|October 8, 2025
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Halle Foss, Yudai Ishiyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 20, 2024
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter studyFumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2025
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative StudyFumihiko Urabe, Kojiro Tashiro, Yu Imai, et al.
The Prostate|April 9, 2025
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched CohortTatsuya Shimomura, Fumihiko Urabe, Katsuki Muramoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 17, 2025
Risk Model for Lymph Node-Positive Prostate Cancer After Radical ProstatectomyKojiro Tashiro, Keiichiro Mori, Masaki Shiota, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
International Cancer Conference Journal|January 27, 2026
Pathological diagnosis and therapeutic management of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinomaKojiro Tashiro, Yoji Nagashima, Mikiko Kaneko, et al.
Clinical Genitourinary Cancer|April 21, 2024
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate CancerKojiro Tashiro, Shoji Kimura, Shunsuke Tsuzuki, et al.
International Journal of Clinical Oncology|July 11, 2023
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancerKeiichiro Miyajima, Hirotaka Suzuki, Fumihiko Urabe, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
Urologic Oncology|October 8, 2025
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Halle Foss, Yudai Ishiyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 20, 2024
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter studyFumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 16, 2025
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative StudyFumihiko Urabe, Kojiro Tashiro, Yu Imai, et al.
The Prostate|April 9, 2025
Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World Propensity Score Matched CohortTatsuya Shimomura, Fumihiko Urabe, Katsuki Muramoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 17, 2025
Risk Model for Lymph Node-Positive Prostate Cancer After Radical ProstatectomyKojiro Tashiro, Keiichiro Mori, Masaki Shiota, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Pageof 10